Table 5. Methicillin-resistant Staphylococcus aureus bloodstream antimicrobial resistance data, Canada, 2019–2023a.
| Antibiotic | Year | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2019 | 2020 | 2021 | 2022 | 2023 | ||||||
| n | % | n | % | n | % | n | % | n | % | |
| Ciprofloxacin | 561 | 70.5 | 460 | 65.6 | 491 | 65.9 | 418 | 66.3 | 466 | 67.1 |
| Clindamycin | 297 | 37.3 | 234 | 33.4 | 221 | 29.7 | 159 | 25.2 | 161 | 23.2 |
| Daptomycin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Erythromycin | 603 | 75.8 | 507 | 72.3 | 510 | 68.5 | 431 | 68.4 | 487 | 70.1 |
| Gentamicin | 35 | 4.4 | 22 | 3.1 | 36 | 4.8 | 20 | 3.2 | 29 | 4.2 |
| Linezolid | 1 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rifampin | 7 | 0.9 | 6 | 0.9 | 10 | 1.3 | 5 | 0.8 | 8 | 1.2 |
| Trimethoprim/sulfamethoxazole | 62 | 7.8 | 46 | 6.6 | 64 | 8.6 | 52 | 8.3 | 67 | 9.6 |
| Tetracycline | 0 | 0.0 | 1 | 0.1 | 6 | 0.8 | 5 | 0.8 | 4 | 0.6 |
| Tigecycline | 15 | 1.9 | 16 | 2.3 | 32 | 4.3 | 37 | 5.9 | 18 | 2.6 |
| Vancomycin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total number of isolates testedb,c | 796 | N/A | 701 | N/A | 745 | N/A | 630 | N/A | 695 | N/A |
Abbreviation: N/A, not applicable
a All MRSA isolates from 2019 to 2023 submitted to the National Microbiology Laboratory were susceptible to nitrofurantoin
b In some years, the number of isolates tested for resistance varied by antibiotic
c Total reflects the number of isolates tested for each of the antibiotics listed above